顺铂联合氟尿嘧啶与顺铂联合多西他赛治疗局部晚期食管鳞状细胞癌
合集下载
- 1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。
肿瘤内科，
郑州 4500080
摘要：
摘要
：目的 探讨顺铂联合氟尿嘧啶与顺铂联合多西他赛治疗局部晚期食管鳞状细胞癌的临床疗效、不良
反应及对患者生活质量的影响。方法
方法 根据治疗方法的不同将 86 例局部晚期食管鳞状细胞癌患者分为对照组
和观察组，每组 43 例，观察组患者采用顺铂联合多西他赛治疗，对照组患者采用顺铂联合氟尿嘧啶治疗。化疗完
doi：
Clinical efficacy of cisplatin combined with fluorouracil or docetaxel in the
treatment of locally advanced esophageal squamous cell carcinoma
CUI Dong1, WU Xiao1, FENG Yu1, LI Ruijie2, QIAN Rulin1 #
into study group (cisplatin + docetaxel) and control group (cisplatin + fluorouracil), with 43 cases in each group. At 3
weeks after chemotherapy, the clinical effects, adverse reactions, QOL and serum carcinoembryonic antigen (CEA) and
耐受性较高，并可在一定程度上提高患者的生活质量，是治疗局部晚期食管鳞状细胞癌的可选方案。
关键词：
关键词
：顺铂；氟尿嘧啶；多西他赛；局部晚期；食管鳞状细胞癌；临床价值
中图分类号：
中图分类号
：R735
735..1
文献标志码：
文献标志码
：A
doi ：10.11877/j.issn.1672-1535.2020.18.04.13
group (P<0.05). 88.37% patients reported improved QOL in study group versus 65.12% in control group, with statistically significant difference observed (P<0.05). The incidence of phlebitis, myelosuppression, nausea and vomiting in study
1
Department of Thoracic Surgery, 2 Department of Oncology, He’nan Provincial Chest Hospital, Zhengzhou 450008, He’
nan, China
Abstract: Objective To analyze the clinical efficacy of cisplatin combined with fluorouracil or docetaxel in the
0.05). Conclusion The combination of cisplatin and docetaxel is more clinically effective, with less adverse reactions
treatment of locally advanced esophageal squamous cell carcinoma (ESCC) and its impact on adverse reactions and quality of life (QOL). Method The clinical data of 86 patients with locally advanced ESCC were analyzed, who were divided
成 3 周后，对两组患者的临床疗效、不良反应、生活质量及治疗前后的血清癌胚抗原（CEA）和鳞状上皮细胞癌抗
原（SCC-Ag）水平进行比较。结果
结果 观察组患者的总有效率为 81.40%，高于对照组的 65.12%，差异有统计学意义
（P﹤0.05）。治疗后观察组患者的生活质量改善率为 88.37%，高于对照组的 65.12%（P﹤0.05）。观察组患者静脉
group were all significantly lower compared with those in control group (P<0.05). Reductions of CEA and SCC-Ag levels
from baseline were noted in both groups, with greater magnitude of reduction in study group than in control group (P<
*论
著*
《癌症进展》
2020 年 2 月 第 18 卷 第 4 期
ONCOLOGY PROGRESS, Feb 2020, Vol. 18, No. 4
374
顺铂联合氟尿嘧啶与顺铂联合多西他赛治疗局部晚期食管鳞状
细胞癌的临床疗效
崔东 1，
吴笑 1，冯雨 1，李瑞杰 2，
钱如林 1 #
2
河南省胸科医院 1 胸外科，
squamous cell carcinoma antigen (SCC-Ag) change from baseline were compared between the two groups. Result After
treatment, the overall response rate in study group was 81.40%, which was significantly higher than the 65.12% in control
炎、骨髓抑制、恶心呕吐的发生率均低于对照组（P﹤0.05）。治疗后两组患者的 CEA、SCC-Ag 水平均低于本组治
疗前，且观察组患者的 CEA、SCC-Ag 水平均低于对照组，差异均有统计学意义（P﹤0.05）。结论
结论 与顺铂联合氟
尿嘧啶方案相比，顺铂联合多西他赛治疗局部晚期食管鳞状细胞癌的临床疗效较好，不良反应发生率较低，患者
郑州 4500080
摘要：
摘要
：目的 探讨顺铂联合氟尿嘧啶与顺铂联合多西他赛治疗局部晚期食管鳞状细胞癌的临床疗效、不良
反应及对患者生活质量的影响。方法
方法 根据治疗方法的不同将 86 例局部晚期食管鳞状细胞癌患者分为对照组
和观察组，每组 43 例，观察组患者采用顺铂联合多西他赛治疗，对照组患者采用顺铂联合氟尿嘧啶治疗。化疗完
doi：
Clinical efficacy of cisplatin combined with fluorouracil or docetaxel in the
treatment of locally advanced esophageal squamous cell carcinoma
CUI Dong1, WU Xiao1, FENG Yu1, LI Ruijie2, QIAN Rulin1 #
into study group (cisplatin + docetaxel) and control group (cisplatin + fluorouracil), with 43 cases in each group. At 3
weeks after chemotherapy, the clinical effects, adverse reactions, QOL and serum carcinoembryonic antigen (CEA) and
耐受性较高，并可在一定程度上提高患者的生活质量，是治疗局部晚期食管鳞状细胞癌的可选方案。
关键词：
关键词
：顺铂；氟尿嘧啶；多西他赛；局部晚期；食管鳞状细胞癌；临床价值
中图分类号：
中图分类号
：R735
735..1
文献标志码：
文献标志码
：A
doi ：10.11877/j.issn.1672-1535.2020.18.04.13
group (P<0.05). 88.37% patients reported improved QOL in study group versus 65.12% in control group, with statistically significant difference observed (P<0.05). The incidence of phlebitis, myelosuppression, nausea and vomiting in study
1
Department of Thoracic Surgery, 2 Department of Oncology, He’nan Provincial Chest Hospital, Zhengzhou 450008, He’
nan, China
Abstract: Objective To analyze the clinical efficacy of cisplatin combined with fluorouracil or docetaxel in the
0.05). Conclusion The combination of cisplatin and docetaxel is more clinically effective, with less adverse reactions
treatment of locally advanced esophageal squamous cell carcinoma (ESCC) and its impact on adverse reactions and quality of life (QOL). Method The clinical data of 86 patients with locally advanced ESCC were analyzed, who were divided
成 3 周后，对两组患者的临床疗效、不良反应、生活质量及治疗前后的血清癌胚抗原（CEA）和鳞状上皮细胞癌抗
原（SCC-Ag）水平进行比较。结果
结果 观察组患者的总有效率为 81.40%，高于对照组的 65.12%，差异有统计学意义
（P﹤0.05）。治疗后观察组患者的生活质量改善率为 88.37%，高于对照组的 65.12%（P﹤0.05）。观察组患者静脉
group were all significantly lower compared with those in control group (P<0.05). Reductions of CEA and SCC-Ag levels
from baseline were noted in both groups, with greater magnitude of reduction in study group than in control group (P<
*论
著*
《癌症进展》
2020 年 2 月 第 18 卷 第 4 期
ONCOLOGY PROGRESS, Feb 2020, Vol. 18, No. 4
374
顺铂联合氟尿嘧啶与顺铂联合多西他赛治疗局部晚期食管鳞状
细胞癌的临床疗效
崔东 1，
吴笑 1，冯雨 1，李瑞杰 2，
钱如林 1 #
2
河南省胸科医院 1 胸外科，
squamous cell carcinoma antigen (SCC-Ag) change from baseline were compared between the two groups. Result After
treatment, the overall response rate in study group was 81.40%, which was significantly higher than the 65.12% in control
炎、骨髓抑制、恶心呕吐的发生率均低于对照组（P﹤0.05）。治疗后两组患者的 CEA、SCC-Ag 水平均低于本组治
疗前，且观察组患者的 CEA、SCC-Ag 水平均低于对照组，差异均有统计学意义（P﹤0.05）。结论
结论 与顺铂联合氟
尿嘧啶方案相比，顺铂联合多西他赛治疗局部晚期食管鳞状细胞癌的临床疗效较好，不良反应发生率较低，患者